GNTA
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- P/B ratio of 0.63 suggests the stock is undervalued relative to assets
- No P/E or PEG available due to lack of earnings
- Graham Number cannot be calculated
Ref Growth rates
- High analyst target price ($6.96)
- No revenue growth data
- Negative ROE of -38.03%
Ref Historical trends
- 1Y Change: -82.4%
- 5Y Change: -93.8%
- Consistent downward trend across all timeframes
Ref Altman Z-Score, Piotroski F-Score
- Strong Current Ratio (14.15)
- Low Debt/Equity (0.35)
- Piotroski F-Score of 2/9 indicates fundamental deterioration
Ref Yield, Payout
- No dividend yield
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GNTA and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GNTA
Genenta Science S.p.A.
Primary
|
-93.8% | -88.7% | -82.4% | -79.4% | -21.2% | -4.4% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CUE
Cue Biopharma, Inc.
Peer
|
-98.5% | -94.2% | -69.9% | -75.0% | -37.5% | -18.2% |
|
CUPR
Cuprina Holdings (Cayman) Limited
Peer
|
-85.5% | -85.5% | -85.5% | -45.3% | +62.6% | +105.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GNTA
Genenta Science S.p.A.
|
BEARISH | $16.02M | - | -38.0% | -% | $0.68 | |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | Compare |
|
CUE
Cue Biopharma, Inc.
|
NEUTRAL | $18.38M | - | -121.1% | -96.9% | $0.19 | Compare |
|
CUPR
Cuprina Holdings (Cayman) Limited
|
BEARISH | $12.9M | - | -139.1% | -% | $0.6 | Compare |
Past News Coverage
Recent headlines mentioning GNTA from our newsroom.